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ABSTRACT 
ilated cardiomyopathy (DCM) is a heart muscle disease characterized by 
dilatation of one or both ventricles together with decreased systolic function. 
Its etiology is still largely unknown. However, immunological alterations such as 
the presence of autoantibodies, elevated cytokines in plasma, and viral genomes in 
the myocardium have been frequently reported. The aim of this thesis was to 
examine T cell function in patients with DCM.  
 First, cytokines in plasma were measured. In accordance with previous reports, 
plasma cytokines of TNF-α, IL-6, IL-10, and CRP were significantly elevated in 
patients with heart failure. Incorporating an etiology of DCM or ischemic heart 
disease together with clinical variables in a multivariate analysis, a diagnosis of 
DCM was found to be independently associated with lower IL-10 levels. Next, 
specific CD4+ T cell response, accumulated cytokines in supernatant, and 
lymphocyte proliferation were measured using flow cytometry-based methods 
following culture of isolated peripheral blood mononuclear cells, and stimulation 
with Staphylococcus enterotoxin B or phytohaemagglutinin. The frequency of IFN-γ-
producing CD4+ (Th1) cells was significantly lower in patients than in healthy 
controls. In contrast, no difference was found in the number of IL-4-producing CD4+ 
(Th2) cells. In addition, IL-10 production in the supernatant and lymphocyte 
proliferation were both significantly lower in patients. To conclude, these 
impairments of IFN-γ and IL-10 are both consistent with an increased susceptibility 
to chronic infections and autoimmunity. 
 Finally, we investigated the frequency of a single nucleotide polymorphism in 
the IFN-γ gene, which alter the transcription level. We found a significant 
association between the IFN-γ polymorphism and susceptibility to DCM. This 
previously unreported finding could be the first diagnostic marker of a DCM of 
autoimmune etiology. 
 In its entirety, this thesis supports the concept that DCM is a late sequela of 
myocarditis leading to a disease of autoimmune character. 
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INTRODUCTION 
THE HEART 
eart failure is defined as a pathophysiological condition in which the heart is 
unable to meet the blood supply demand of the body. Its prevalence has 
increased significantly during the last decades. About 2% of the population suffers 
from heart failure, which is a major cause of hospitalisation and death in the western 
world. Heart failure is considered a heterogeneous syndrome in which not one, but 
several different pathophysiological conditions may lead to clinical manifestations. 
However, one major cause of heart failure is cardiomyopathy. 
 The definition and classification of cardiomyopathy have varied over the years. 
Recently, the European Society of Cardiology defined cardiomyopathy as a 
‘myocardial disorder in which the heart muscle is structurally and functionally 
abnormal in the absence of coronary artery disease, hypertension, valvular disease 
and congenital heart disease’. It has been proposed to divide cardiomyopathy into 
five types, i.e., dilated, hypertrophic, arrhythmogenic right ventricular, restrictive, 
and unclassified cardiomyopathy [Elliott 2008]. 
Dilated cardiomyopathy 
ilated cardiomyopathy (DCM) is the most frequent form of heart failure in 
young adults, with an incidence of 5–8 cases per 100 000 individuals per year. It 
has a poor prognosis and is one of the major causes of heart transplantation in 
Sweden [Socialstyrelsen 2008]. DCM is characterized by dilatation of one or both 
ventricles, usually the left ventricle, together with decreased systolic function. Its 
etiology is largely unknown. Approximately 30–50% of patients have a familial form 
of DCM [Burkett 2005]. In fact, several different mechanisms might exist in DCM, 
such as viral-induced, autoimmune, and inflammatory mechanisms. Evidence for all 
three, i.e., the presence of viral genomes in the myocardium, autoantibodies against 
heart antigens, and increased immune activity in terms of elevated levels of plasma 
cytokines, is reported in the literature [Kuhl 2005; Magnusson 1994; Levine 1990; 
Mann 2002]. 
H 
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THE IMMUNE SYSTEM 
he immune system is one of the most complex networks acting in the human 
body. It is divided into the fast non-specific innate immunity and the slower 
more specific adaptive immunity, although both types act together. Both are vital for 
protection against invading microbes such as viruses, bacteria, and protozoa, and 
for the maintenance of self-tolerance preventing autoimmune disorders.  
 T cells are of major importance in the adaptive immunity. During the 
development of T cells, interactions with stromal cells and the presence of various 
differentiating factors and cytokines are important. Initial stages of this 
development do not require the presence of antigens. However, once T cells express 
mature antigen receptors on the cell surface, they become antigen dependent in 
order to survive and differentiate. The adaptive immunity is time-consuming to 
mobilize, it take days to be fully activated due to the rearrangement of receptor 
genes needed to generate antigen specificity.  
 Central self-tolerance is established by the presentation of self-antigens to 
developing T cells in the thymus. T cells binding self-antigens with high affinity are 
subjected to apoptosis, while those not binding are released into the circulation. 
Occasionally, cells binding self-antigens escape the maturation site and are found 
circulating in the periphery. This dramatically increases the risk of autoimmune 
reactions. Autoimmune reactions, i.e., break of peripheral tolerance, however, is 
controlled by regulatory T cells.  
 Cytokines are the most important molecular components of the immune system 
during infections, autoimmunity, and self-tolerance. In the 1990s, cytokines were 
designated as either pro- or anti-inflammatory depending on whether they 
promoted or suppressed inflammation. Today the view is far more complicated, and 
many cytokines are now considered to have pleiotropic effects. Cytokines are 
produced by different cell subsets and their function depends on the cell from which 
they are produced, the target cell, and the surrounding milieu. 
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T CELL DEVELOPMENT 
he T cell derived its letter designation from the site of maturation, the thymus. 
However, T cell development originates from bone marrow-derived 
progenitors. Notch signalling has been suggested to play an obligatory and selective 
role in the induction of the T cell lineage. In a Notch-deficient mouse model, 
progenitors failed to commit to the T cell lineage in the thymus while all other 
haematopoietic cell lineages developed normally [Radtke 1999]. 
 Surface expression of various proteins reflects the stage of maturation. 
Maturation of T cells includes the rearrangement of the α- and β-chains of the T cell 
receptor (TCR) and the expression of the surface markers CD4 and CD8. Expression 
of the Th-POK transcription factor directs developing T cells to the CD4 lineage, 
while its absence seems to commit T cells to the default CD8 lineage [He 2005]. Once 
expressing a functional TCR, negative and positive selection takes place and results 
in T cells specific to foreign antigens (Figure 1) [Spits 2002].  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Overview of the T cell development in the thymus.  
T 
β chain 
rearrangement   
α chain 
rearrangement 
      
αβ-TCR + CD3/CD4  
 or CD3/CD8  
expression   
Thymocyte                          pre-TCR                            αβ-TCR                 Positive and negative                                    
s                                                                                                                                   selection 
Periphery 
Apoptosis    
 
INTRODUCTION 
 
 
 
 - 14 - 
The TCR recognizes both the major histocompatibility complex (MHC) molecule 
itself and a short peptide derived from the processed antigen presented by the MHC 
molecule. T cells undergo both positive and negative selection before entering the 
periphery. During positive selection, T cells binding with moderate affinity to self-
MHC molecules presented by cortical epithelial cells will receive the survival signal, 
selecting them for the next selection phase, while those binding with low affinity are 
subjected to apoptosis. In negative selection, T cells binding the self-MHC molecules 
presenting a self-antigen will be eliminated, while those not binding will enter into 
the periphery. Approximately 95% of all T cells fail both selection steps and die 
within the thymus. Negative selection is an important mechanism for 
immunological tolerance, eliminating self-reactive T cells while allowing maturation 
only of those T cells specific to foreign antigens together with self-MHC molecules 
[von Boehmer 1990]. In the periphery, CD4+ T cells recognize MHC class II 
molecules together with antigenic peptides, while CD8+ T cells recognize MHC class 
I molecules binding peptides from foreign antigens.  
 The most common T cell population comprises those expressing the αβ-chain 
TCR. They are expressed on approximately 95% of the circulating T cells and are 
found in secondary lymphoid organs, such as the spleen, lymph nodes, and mucosal 
lymphoid tissues. They respond to infection by activating the humoral immune 
response and by lysis of infected target cells. They are dependent on antigen 
processing and presentation to initiate and maintain their effector function. 
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EFFECTOR CELLS 
riggering the TCR by antigen recognition induces naïve T cells to proliferate 
and differentiate into a variety of effector cells, such as T helper, T cytotoxic, 
and regulatory T cells. These subsets determine the type and magnitude of immune 
response, depending on the presented antigen and the surrounding cytokine milieu. 
In addition to T cells belonging to the adaptive arm of the immune system, NK and 
NKT cells are other important effector cells for a functional immune system. 
Activation of effector cells following antigen presentation by dendritic cells 
rucial to the activation of effector T cells is the antigen presentation carried out 
by dendritic cells (DCs). DCs are a major cell type of the innate immune 
system known to link innate to adaptive immunity [Banchereau 1998]. The 
recognition of a specific antigen presented on the surface of an antigen-presenting 
cell is the first of two signals required for T cell activation. Immature DCs capture 
and process antigens, load the peptides onto the MHC II molecules, in the case of 
exogenous antigens, or onto the MHC I molecules if the antigens are, for example, 
viral proteins synthesized within the cell or released during apoptosis. Newly 
formed MHC II-antigen complexes have relatively long half-lives exceeding 100 h, 
in contrast to the MHC I-antigen complex which has a half-life of only 10 h [Cella 
1997; Cella 1999]. 
 Mature DCs up-regulate their expression of B7.1 (CD80) and B7.2 (CD86) 
molecules on the cell surface. These molecules bind the CD28 receptor expressed on 
T cells and mediate the second and final signal for T cell activation. CD28 triggers 
entry of the T cell into the G1 phase of the cell cycle and induces transcription of the 
cytokine IL-2, leading to sustained activation and TCR signalling [Bretscher 1999]. In 
the absence of this second signal, T cells become anergic and apoptotic. In contrast 
to CD28, CTLA-4 (CD152) functions as an inhibitory receptor for B7.1 and B7.2, 
down-modulating the immune response by inhibition of cytokine production, 
down-regulating IL-2 receptor expression, and inducing cell cycle arrest. Unlike 
CD28, which is constitutively expressed and down-regulated following binding to 
T 
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B7 molecules, CTLA-4 is up-regulated following CD28 engagement with B7 and 
induces anergy in activated T cells (Figure 2) [Walunas 1996]. 
 
 
 
 
Figure 2. One way of inducing apoptosis and down-regulation of an active immune response. MHC, 
major histocompatibility complex; TCR, T cell receptor; APC, antigen-presenting cell.  
T-helper cells 
central event in both the cellular and humoral immune responses is the 
activation of T helper (Th) cells. The Th cells are unusual in the sense that 
they do not have cytotoxic or phagocytic functions and are unable to kill infected 
host cells. In that sense, they could be considered useless to the immune system. 
That is not the case, however, since they have been shown to have important 
functions, such as activating both cytotoxic T cells and phagocytic cells, and 
initiating antibody class switching. 
 Following the initial activation steps, Th cells up-regulate numerous genes 
needed in the immune response. These are grouped according to how early they can 
be detected following activation, i.e., immediate, early, and late genes (Table 1) 
[Crabtree 1989]. IL-2 is the main Th cell-proliferative cytokine, the production of 
which is induced by B7-CD28 signaling as early as 45 min following antigen 
recognition, and it is responsible for massive Th cell proliferation.  
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Th cells are further divided into Th1 and Th2 cells, depending on their function and 
cytokine production. It has been shown that B7.2 is required for polarization toward 
the Th2 cell lineage, while B7.1 is considered a more general differentiative signal 
[Freeman 1995]. Th1 cells are responsible for activating a cell-mediated response 
including macrophages and cytotoxic T cells for phagocytosis and killing of 
intracellular pathogens. It is well known that IL-12 produced by mature DCs directs 
Th cells into a IFN-γ-producing Th1 cell subset, an effect mediated by the interaction 
of CD40 on the DC with CD40L on the Th cell [Heufler 1996; Cella 1996]. In contrast 
to CD40/CD40Ligand interaction, the OX40/OX40Ligand interaction and the 
presence of IL-4 in the surrounding milieu have been shown to influence the 
differentiation of Th2 cells, secreting IL-4, IL-5, IL-10, and IL-13 [Ito 2004]. Surface 
markers able to differentiate between the Th1 and the Th2 subsets are still lacking, 
and the most promising way to investigate these subsets is by studying cytokine 
production. 
 Two genes have been shown to regulate prototypic Th1 and Th2 cytokine 
production, IFN-γ and IL-4, respectively. The transcription factor Tbet initiates 
commitment to the Th1 subset from naïve T cells and controls the production of the 
prototypic IFN-γ cytokine, whereas GATA-3 has been shown to be selectively 
expressed in Th2 cells and to directly activate the IL-4 promoter. Reciprocal 
inhibition between these two subsets is known to occur both on the transcription 
levels and by means of the produced cytokines [Szabo 2000; Zheng 1997]. 
Cytotoxic T cells 
he major role of cytotoxic T cells is to kill infected somatic cells and other 
damaged or dysfunctional cells, such as tumour cells. Cytotoxic T cells express 
both a TCR and a CD8 molecule and are activated when recognizing an antigen 
presented on the MHC class I molecule; to be fully activated, they are dependent on 
Th cells [Schoenberger 1998; Melief 2003]. When activated, they release the cytotoxic 
enzymes perforin and granzyme, which activate the FasLigand apoptotic pathway 
of the target cell. Cytotoxic T cells produce cytokines such as IFN-γ, TNF-α, IL-2, IL-
4, and IL-10. In addition, some cytotoxic T cells also have a suppressive function 
[Mosmann 1997]. 
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Table 1. Time course of gene expression by Th cells following antigen recognition.  Adapted from 
Crabtree (1989). 
 
Gene product 
 
Function 
Time mRNA 
expression begins 
 
Location 
Ratio 
A/NA 
                Immediate 
NF-AT Th-specific 
transcription factor 
20 min Nucleus 50 
NF-κΒ Transcription factor 30 min Nucleus >10 
    Early 
IFN-γ Cytokine 30 min Secreted  >100 
IL-2 Cytokine 45 min Secreted >1000 
IL-3 Cytokine 1–2 h Secreted >100 
TGF-β Cytokine <2 h Secreted >10 
IL-2 receptor (p55) Receptor 2 h Cell membrane >50 
TNF-β Cytokine 1–3 h Secreted >100 
IL-4 Cytokine <6 h Secreted >100 
IL-5 Cytokine <6 h Secreted >100 
IL-6 Cytokine <6 h Secreted >100 
GM-CSF Cytokine 20 h Secreted ? 
  Late 
HLA-DR MHC class II 
molecule 
3–5 days Cell membrane 10 
NF-AF, nuclear factor of activated T cells; NT-κΒ, nuclear factor-kappa beta; IFN-γ, interferon 
gamma; IL-, interleukin; TNF-β, tumour necrosis factor-beta; GM-CSF, granulocyte monocyte colony-
stimulating factor; HLA-DR, human leukocyte antigen-DR; A/NA, ratio of activated to non-activated 
cells. 
Regulatory T cells  
nother important T cell subset is the regulatory T (Treg) cells, which have 
received massive attention in recent years, although definitive answers as to 
how they develop, their phenotypic characterization, and exact mechanism(s) of 
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action are still lacking [Sakaguchi 2008]. However, it is known that they act by 
regulating the magnitude of the activated immune system in order to maintain 
homeostasis and tolerance to self-antigens. Immunological tolerance cannot be 
explained solely by clonal deletion during T cell development in the thymus, since 
self-reactive T cells are found in healthy individuals. In the mid 1990s, the CD4+ Th 
cells expressing the α-subunit of the IL-2 receptor (CD25) were identified as the 
naturally occurring Treg cells, which constitute approximately 10% of the CD4+ 
cells. In 1998 it was shown that the function of autoreactive T cells was blocked by 
CD4+CD25+ regulatory cells [Suri-Payer 1998]. However, since resting and activated 
human T cells also were shown to express CD25, this phenotypical characterization 
was not sufficient. The most specific marker so far reported for CD4+CD25+ 
naturally occurring Treg cells is the forkhead box transcription factor (Foxp3), which 
was also found to be essential for their development [Fontenot 2003]. The effect of 
naturally occurring Treg cells in vitro is well known, while the effect in vivo   remains 
unidentified. Naturally occurring Treg cells are found to affect almost all cell types 
involved in the immune system, including by the following means: inhibiting the 
induction as well as the effector and memory functions of Th2 cells; inhibiting the 
proliferation, Ig production, and class switching of B cells; and inhibiting NK and 
NKT cytotoxicity as well as the function and maturation of DCs [Miyara 2007]. For 
naturally occurring Treg cells to become suppressive, they require antigenic TCR 
activation; however, once activated, their suppressive effects are completely antigen 
non-specific [Thornton 2000]. 
 Another group of Treg cells has been demonstrated, namely, the inducible Treg 
cells. They were first recognized following antigenic stimulation of human and 
mouse CD4+ cells in vitro in the presence of IL-10. Stimulation resulted in an IL-10-
producing, but not an IL-2- or IL-4-producing, CD4+ population able to inhibit 
antigen-specific immune response [Groux 1997]. As early as 1994, the importance of 
IL-10-producing cells was demonstrated. In patients with severe combined 
immunodeficiency, IL-10-producing cells suppressed the host-reactive T cells 
following HLA mismatch transplantation [Bacchetta 1994]. Inducible Treg cells seem 
to exert their suppressive effects mainly via cytokine production, unlike naturally 
occurring Treg cells, which use cell–cell contact and cytotoxicity. Inducible Treg cells 
mainly dampen the immunological response in an antigen-dependent manner, 
 
INTRODUCTION 
 
 
 
 - 20 - 
while naturally occurring Treg cells act more directly on cell activity independent of 
antigen stimulation. 
Natural killer cells 
n important cell type in innate non-specific immunity is the natural killer 
(NK) cells. NK cells play an important role in the early response to invading 
pathogens while the adaptive immunity is being activated, as well as in fighting 
tumours. They possess cytotoxic activity following activation by cytokines and via 
their activating and inhibitory cell surface receptors, which distinguish between self 
and non-self cells. NK cells are phenotypically characterized by their cell surface 
expression of CD56 and CD16 and the lack of CD3 expression. Approximately 90% 
of the NK cell population has a low density of CD56 (CD56dim) and a high density of 
CD16 (CD16bright) and is the most cytotoxic NK population. The CD56bright, 
CD16dim/neg subset constitutes approximately 10% and is the major cytokine-
producing NK population. These cells produce large quantities of IFN-γ in 
particular, but also of other cytokines such as TNF-α and IL-10 [Lanier 1986; Stetson 
2003]. Results from animal models report the order of NK cell frequency in the body 
to be lungs > liver > peripheral blood mononuclear cells > spleen > bone marrow > 
lymph node > thymus. They constitute approximately 9% of total lymphocytes in 
the lungs but slightly under 1% in the lymph nodes [Gregoire 2007]. 
Natural killer T cells 
nother important cell population is natural killer T (NKT) cells. This 
population is defined as an αβTCR+ T cell subset expressing NK cell-specific 
receptors. They are suggested to be the frontier between innate and adaptive 
immunity and to exert cytotoxic activity. Unlike T cells, NKT cells do not recognize 
antigens presented on MHC class I or II molecules. Instead, they are known to be 
activated by lipid antigens presented on the CD1d molecule, and are therefore also 
referred to as CD1-restricted T cells [Godfrey 2004]. Except for the expression of 
CD56 and CD16 observed on NK cells, NKT cells also express the T cell-specific 
A 
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markers CD3 and TCR. The hallmark of mature NKT cells is the rapid production of 
tremendous amounts of IFN-γ and IL-4. They also produce other cytokines, such as 
IL-2, TNF-α, IL-5, IL-13, and GM-CSF. In animal models, NKT cells have been found 
in the thymus, lymph nodes, bone marrow, spleen, blood, liver, and lungs. They are 
most abundant in the lungs, constituting approximately 15% of the immune cells 
while they constitute less than 5% in other organs [Gregoire 2007]. 
 It has been suggested that NKT cells play a role in both infection and 
autoimmunity. Defective NKT cells have been reported in patients with various 
autoimmune diseases, such as multiple sclerosis, systemic lupus erythematosus, and 
rheumatoid arthritis. Their capacity to down-regulate T cell immunity has been 
shown in vivo, where CD1d-deficient mice failed to develop systemic tolerance 
[Ronchi 2008; van der Vliet 2001]. 
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EFFECTOR MOLECULES – THE CYTOKINES 
ytokines are molecules needed for communication between cells in order to 
activate and inhibit immune responses. Many cytokines are now believed to 
have pleiotropic effects, and since some cytokines are of special interest in this thesis, 
a short description of each one and their characteristics will follow. 
Interferons 
ome of the most prominent proinflammatory cytokines are the interferons 
(IFNs), named for their main function of interfering with viral replication. The 
importance of IFNs goes beyond that of antiviral activity and includes an 
immunoregulatory function, which results in epigenetic changes of indeterminate 
naïve Th cells into either a Th1 or a Th2 phenotype. The IFNs are divided into type I 
(α,β) and type II (γ) according to their receptor complex and sequence homology. 
Production of type I IFNs is induced by double-stranded viral RNA and may be 
produced by, for example, macrophages, monocytes, and fibroblasts. IFN-γ is mainly 
produced by Th1 cells but also by cytotoxic T cells following TCR stimulation during 
adaptive immune responses, whereas NK and NKT cells are responsible for its 
production during innate immune activity in response to macrophage-derived 
cytokines, such as TNF-α and IL-12. In addition, IFN-γ may also be produced in 
response to IL-18, IFN-α and -β, and γδ+ T cells (a T cell population constituting less 
than 5% of total lymphocytes); DCs and macrophages have also been shown to 
secrete IFN-γ [Boehm 1997]. 
 The expression of IFN-γ is regulated on both the transcriptional and 
posttranscriptional levels. A variety of transcription factors, including nuclear factor 
(NF)-κB, T-bet, and GATA-3, have been shown to regulate IFN-γ transcription [Sica 
1997; Szabo 2000; Zheng 1997]. NF-κB can induce IFN-γ expression indirectly by 
promoting the expansion of IFN-γ-producing cells or through the induction of IL-12, 
which in turn induces IFN-γ expression [Tato 2003]. Like many other cytokines, 
complex cross-talk exists between the IFNs; signalling by IFN-γ has been shown to 
depend on the IFN-α,β receptor components [Takaoka 2000]. 
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Tumor necrosis factor-α 
umor necrosis factor (TNF)-α, first discovered as an endotoxin-induced 
glycoprotein, exists in membrane-bound and soluble forms. The main source of 
TNF-α is macrophages and T cells. Other cell types, such as B and NK cells, mast 
cells, neutrophils, endothelial cells, smooth and cardiac muscle cells, have also been 
shown to produce minor amounts of TNF-α. TNF-α promotes inflammation by up-
regulating various adhesion molecules on epithelial cells, which in turn attract 
inflammatory cells to the site of inflammation. Increased plasma levels were 
observed during inflammation and shown to correlate with the severity of infection 
[Kwiatkowski 1990]. 
 TNF receptor-deficient mice were shown to be resistant to lethal dosages of both 
lipopolysaccharides (i.e., the induction of endotoxic shock) and Staphylococcus aureus, 
but in contrast displayed impaired clearance of the mycobacterium Listeria 
monocytogenes [Pfeffer 1993]. Although TNF-α is considered important for mounting 
an inflammatory response, excessive levels are harmful to the host. Major production 
of TNF-α from monocytes during endotoxic shock, together with the activation of 
neutrophils and coagulation factors, result in respiratory distress, multiple organ 
failure, and death [Morrison 1987]. Excessive levels of TNF-α are also believed to 
result in autoimmune reactions. TNF-α blocking treatment has been extensively used 
in rheumatoid arthritis, Crohn’s disease, and psoriasis with promising results 
[Feldmann 2001]. However, TNF-α blocking treatment is not completely without 
adverse effects; for example, it has been shown to enhance the production of type I 
IFNs [Palucka 2005]. In fact, adverse effects were reported from clinical trials for 
heart failure, where treatment increased the risk of disease [Kwon 2003;]. 
Interleukin-2  
ne of the first cytokines characterized on a molecular level was interleukin-2 
(IL-2). It was found to have growth-promoting activity on bone marrow-
derived T cells. Following T cell activation, IL-2 is rapidly synthesized, which in turn 
up-regulates the IL-2 receptor expression in an autocrine manner, leading to the 
expansion of both CD4+ and CD8+ T cells. CD4+ cells are the main source of IL-2. 
T 
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However, minor amounts of IL-2 are also produced by B cells and DCs. The main 
function of IL-2 is to regulate the magnitude and duration of an activated immune 
response, inducing proliferation and differentiation, and to down-regulate an 
ongoing immune response to prevent autoimmune reactions. The latter is regulated 
by the transient production of IL-2, where the absence of antigenic stimulation leads 
to the death of activated T cells. IL-2 initiates pro-apoptotic pathways by inducing 
FasLigand expression on T cells [Van Parijs 1998]. It also has activating effects on NK 
cells, inducing the production of TNF-α and IFN-γ from NK cells, and acts 
synergistically with IL-12 to enhance NK cell cytotoxicity [Khatri 1998]. As for IFN-γ, 
IL-2 is also able to bind NF-κB, which increases cytokine gene expression [Kane 
2002]. In contrast, the CTLA-4/B7 signalling induced by antigenic stimulation 
inhibits IL-2 production. 
Interleukin-4 
he major anti-inflammatory cytokine interleukin-4 (IL-4) was first discovered as 
a cytokine able to promote proliferation and differentiation of anti-IgM-treated 
B cells into IgG- and IgE-producing plasma cells. IL-4 is produced by Th2, NK and 
mast cells, eosinophils, and basophils. IL-4 function as inducer of the humoral B cell 
response by stimulating the proliferation and differentiation of B cells, inducing Ig 
class switching, up-regulating MHC class II expression on B cells and macrophages, 
and inducing Th2 polarization of T cells. IL-4 has an important immune regulatory 
function, characterized by down-regulation of macrophages and monocytes 
synergistically with other cytokines, such as IL-1, IL-6, IL-8, IL-12, and TNF-α. IL-4 
has been used in animal models for treating Th1-driven autoimmune diseases, such 
as allergic encephalomyelitis and collagen-induced arthritis, with promising results 
[Schulze-Koops 2001; Horsfall 1997]. 
Interleukin-6 
nteraction between T and B cells during antibody production was reported in 
1968 without knowing the precise mechanism. Years later, interleukin-6 (IL-6) was 
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characterized as an important cytokine for terminal differentiation of plasma cells, 
antibody production, and the inflammatory response. In the early 1990s, it was 
shown that the antiviral activity in IL-6-deficient mice decreased by 90% following 
injection with stomatitis virus [Kopf 1994]. 
 Today IL-6 is considered a pleiotropic cytokine, mainly produced by monocytes, 
macrophages, Th2 cells, and stroma cells. It is one of the most potent stimulators of 
acute phase inflammatory proteins such as C-reactive protein (CRP) and serum 
amyloid A [Gauldie 1987]. In addition, IL-6 induces T cell growth and cytotoxic T cell 
differentiation by augmenting IL-2 receptor expression and the potent 
proinflammatory cytokine inducer IL-12. IL-6 is also believed to play a role in T cell 
development in the thymus [Le 1988]. It induces differentiation of macrophages and 
up-regulates the expression of various adhesion molecules on endothelial cells. In 
conclusion, IL-6 is considered a key cytokine for the transition from acute to chronic 
inflammation, which is demonstrated by the transition from neutrophil to monocyte 
recruitment during inflammation [Kaplanski 2003]. IL-6 is thought to be involved in 
autoimmune reactions, where blocking its receptor has been shown to be a beneficial 
treatment for rheumatoid arthritis [Maini 2006]. 
Interleukin-10 
nterleukin-10 (IL-10) was first described as cytokine synthesis inhibitory factor 
produced by Th2 cells in mice and shown to inhibit cytokine production by Th1 
cells [Fiorentino 1989]. Today, IL-10 is known to be produced by a variety of cell 
types, including B cells, mast cells, eosinophils, macrophages, DCs, cytotoxic T cells, 
and regulatory T cells. The exact mechanism by which IL-10 exerts its suppressive 
activity is still unclear. However, IL-10 is known to be involved in inhibiting 
macrophage and DC functions, leading to decreased production of proinflammatory 
cytokines [Kuhn 1993; Murphy 1994]. However, IL-10 also inhibits MHC class II 
expression, which in turn increases the risk of chronic infection due to impaired 
antigen presentation and clearance. In addition, IL-10 specifically decreases TNF-α 
production by macrophages, resulting in a limited ability to kill intracellular 
pathogens [Gazzinelli 1996]. Production of IL-10 has been shown to be important in 
reducing excessive IFN-γ. Interestingly, in mice infected with Toxoplasma gondii, the 
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IFN-γ-secreting Th1 cells were also shown to produce IL-10. The IL-10 production 
was induced more rapidly in recently activated than in resting cells, indicating that 
IL-10 has a regulatory function [Jankovic 2007]. 
 
The cytokines constitute a complex network of effector molecules; Table 2 
summarizes the cellular source of the cytokines and their main function. 
Table 2. Cytokines, their cellular sources, and main function. 
Cytokine Cellular source Function 
IL-2 Th1 cells, B cells, DC Regulates the magnitude and duration of the 
immune response 
Induces proliferation and differentiation 
IL-4 Th2 cells, mast cells, 
basophils and eosinophils 
Induces B cell response, Ig class switching, Th2 
polarization, up-regulates the MHC class II 
expression on B cell and DC 
IL-6 Th2 cells, monocytes, MQ Induces T cell growth and differentiation of 
cytotoxic T cells 
Induces differentiation of MQ and up-regulates 
the expression of adhesion molecules 
Stimulates the production of acute-phase proteins 
IL-10 T and B cells, MQ, DC, 
mast cells, eosinophils 
Regulatory functions, i.e., inhibiting MQ and DC 
functions and decreasing proinflammatory 
cytokine production 
Down-regulates the MHC class II expression 
TNF-α MQ, NK, mast cells, T and 
B cells 
Promotes inflammation 
IFN-α Virus-infected cells Induction of resistance to viral infection 
IFN-β Virus-infected cells Induction of resistance to viral infection 
IFN-γ Th1 cells, NK and NKT 
cells 
Inhibits Th2 cells, activates MQ, regulatory 
functions 
IL, interleukin; TNF, tumor necrosis factor; IFN, interferon; Th, T helper; DC, dendritic cells; MQ, 
macrophage; MHC, major histocompatibility complex; NK, natural killer; NKT cells, natural killer T. 
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IMMUNOLOGICAL ALTERATIONS IN DCM 
he cause of DCM is still largely unknown. One hypothesis is that DCM is 
initiated by a viral myocarditis, which, due to immunological malfunction, does 
not fully resolve and therefore develops into a chronic disease of an autoimmune 
character [Kawai 1999; Mason 2003]. However, DCM is a heterogeneous disease and 
this hypothesis might explain disease development in a subset of patients.  
 Myocarditis and DCM are suggested to represent the acute and chronic states of 
an organ-specific autoimmune disease of the myocardium [Richardson 1996; Caforio 
1996; MacLellan 2003]. As early as 1968, Orinius reported heart disease in humans’ 
years after a coxsackie virus infection. Twenty years later, Bowles et al. reported 
coxsackie B virus-specific RNA in myocardial biopsies from patients with 
myocarditis and DCM [Orinius 1968; Bowles 1986].  
 In 1957, Witebsky and Rose postulated the criteria of autoimmune disease, criteria 
that are met in myocarditis and DCM [Witebsky 1957]. In the late 20th century, the 
specificity and functional activity of autoantibodies against the β1-adrenergic 
receptor were defined [Magnusson 1990; Magnusson 1994]. Since then, the adaptive 
humoral response to various cardiac antigens has been well explored and several 
heart-directed autoantibodies have been found circulating in patients with DCM. In 
contrast, little research has been done examining the cellular response in these 
patients. However, numerous studies have examined patients with DCM and found 
various immunological characteristics associated with autoimmunity and infection.  
 Table 3 summarizes the immunological alterations found in DCM. These strongly 
indicate that DCM is a disease of autoimmune and infectious origin. Attention now 
needs to be directed toward the cellular response and its impact on the 
pathophysiology of DCM. 
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Table 3. Examples of infectious and autoimmune characteristics found in dilated cardiomyopathy.  
Immunological characteristics  Reference 
Viral genomes in the myocardium CMV, EBV Kühl 2005 
Elevated plasma cytokines TNF-α, IL-6, IL-10 Levine 1990, Torre-Amione 
2005 
Aberrant adhesion molecule expression 
in the myocardium 
ICAM, VCAM  Devaux 1997, Noutsias 2003  
Expression of HLA class II in the 
myocardium 
 Caforio 1990, 1994 
Circulating autoantibodies β1-AR, myosin, 
mitochondrial 
Magnusson 1994, Caforio 
1992, Schultheiss 1985                  
Infiltrating T cells in the myocardium  Kühl 1996, Noutsias 2002 
CMV, cytomegalovirus; EBV, Epstein–Barr virus; ICAM, intercellular adhesion molecule; VCAM, 
vascular cell adhesion molecule; TNF-α, tumor necrosis factor-α; IL, interleukin; β1-AR, β1-adrenergic 
receptors. 
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AIMS 
he cause of DCM is still largely unknown. Autoantibody production, presence 
of viral genomes in the myocardium, and increased peripheral cytokine levels 
have been explored in recent decades. However, T cell function in DCM has 
received considerably less attention. The main focus of this thesis was therefore to 
investigate T cell function in patients with DCM. Our initial hypothesis was that 
patients with DCM would have an altered T cell function, most likely evident in 
increased IL-4 production. The specific aims of this thesis were therefore to:  
 
 Establish methods and experimental conditions for measuring 
specific T cell functions in patients with DCM 
 Study natural variances in relevant genes coding for 
immunological proteins for possible influence on the 
pathophysiology of DCM 
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METHODOLOGICAL CONSIDERATIONS 
eneral descriptions of the study subjects and methods are given in each paper. 
In this section, they are described in detail and specific considerations are 
discussed.  
Idiopathic dilated cardiomyopathy 
atients with idiopathic dilated cardiomyopathy (DCM) were recruited from a 
prospective multicenter study of DCM (papers I–III). Patients were recruited 
consecutively from seven Swedish hospitals starting in May 1997. The inclusion 
criteria were left ventricle dilatation of >32 mm/m2 and an ejection fraction <0.45. 
The exclusion criteria were: ischemic heart disease diagnosed by coronary 
angiography or a history of myocardial infarction, hypertension with a blood 
pressure of >170/100 mm hg, significant valvular disease, significant systemic 
infection, excessive alcohol consumption, insulin-treated diabetes, endocrine 
disorders, cancer treatment including irradiation, and tachycardia-induced 
cardiomyopathy or other primary cardiomyopathy, such as hypertrophic 
cardiomyopathy [Magnusson 2005]. 
 In paper III, n = 156 patients were also recruited from an epidemiological survey 
of idiopathic DCM performed in five counties of western Sweden from 1980 to 1987. 
All patients were investigated using echocardiography and had a clinical 
examination including ECGs, chest radiographs, and routine laboratory tests 
[Andersson 1995]. Patients with idiopathic DCM and patients with heart failure of 
unknown cause diagnosed with left ventricular dilatation and systolic dysfunction, 
i.e., ejection fraction <0.50 were included. Coronary angiography was 
retrospectively performed in a subset of theses patients, 15% of whom were found to 
have coronary disease [Andersson 1995]. This means that in paper III the DCM 
group may include <6% patients with ischemic heart disease. 
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Ischemic heart disease 
atients with ischemic heart disease (IHD) attending the Sahlgrenska University 
Hospital for investigation or treatment of chronic heart failure were included 
as a control group (paper I). These patients had been diagnosed with coronary 
disease by prior angiography. Patients with IHD were hospitalized for evaluation 
before heart transplantation, implantation of an internal cardioverter defibrillator, or 
implantation of a biventricular pacing system.   
 By using a control group with heart failure, it was possible to investigate 
etiological differences, which is not possible using a healthy control group. 
Healthy controls 
healthy control group of adult subjects was randomly selected from the 
western Sweden county population, since the majority of patients with DCM 
(78%) also were recruited from the western regions of Sweden. 
 In paper II, a healthy control allows identification of altered T cell function in 
patients with DCM, a defect that could also be of mechanistic nature. In paper III the 
use of a large control group from the general population allows identification of 
susceptibility genes.  
 All studies complied with the Declaration of Helsinki and were approved by the 
Ethics Committee of the Medical Faculty, Göteborg University, Sweden. All study 
subjects gave informed written consent to participate. 
Clinical parameters 
he New York Heart Association (NYHA) functional class, which places the 
patients in one of four categories relating to limiting symptoms during 
physical activity, is determined by the treating physician. Ejection fraction is 
measured by two-dimensional echocardiography. A right heart catheterisation was 
perfomed at rest for hemodynamic evaluation, including intracardiac pressures and 
cardiac output obtained by thermodilution technique. Cardiac index is calculated by 
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cardiac output, which is the stroke volume x heart rate, divided by the body surface 
area; this relates heart performance to individual size. 
Analysis of plasma cytokines  
he usual method for quantifying plasma cytokines is the enzyme-linked 
immunosorbent assay (ELISA). ELISA is a reliable method that makes use of 
the highly specific and strong binding between an antibody and an antigen, in this 
case, the cytokine. However, cytokines are rapidly degraded following extreme 
changes in temperature and should therefore be analysed using samples that have 
not been previously thawed, or thawed as few times as possible. The coefficient of 
variation (CV) for TNF-α, IL-6, and IL-10 were reported from the manufacturer as 
13.4%, 7.7%, and 11.3%, respectively. An investigation of the CV in our laboratory 
was similar for TNF-α and IL-6, 15.2% and 6.0%, respectively, while for IL-10 it was 
38.8%. When the concentration differed greatly between duplicates or between two 
individual analyses, samples were re-analysed. 
Isolation and stimulation of PBMC 
enous blood samples were collected in lithium–heparin tubes from which 
peripheral blood mononuclear cells (PBMC) were isolated using Ficoll Paque. 
Ficoll Paque yields a cell preparation with 60 ± 20% recovery of lymphocytes, 95 ± 
5% recovery of mononuclear cells, 3 ± 2% recovery of granulocytes, 5 ± 2% recovery 
of erythrocytes, and <0.5% recovery of the total platelet content present in the blood. 
Between collection and isolation, the blood was kept at room temperature and 
isolation was performed within 4 h. Kaplan et al. reported that a delay in cell 
preparation exceeding 24 h affected lymphocyte markers and blastogenic responses 
[Kaplan 1982]. To minimize undesirable activation of lymphocytes during culture 
procedures, human AB sera were used. AB sera contain no antibodies against any 
blood group, i.e., A, B, or O, and are therefore the most suitable sera to use when 
culturing human blood cells.  
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Optimization of antigen concentrations for lymphocyte stimulation was performed 
using the CFSE proliferation method following three days of culture. For PHA and 
SEB, 1 and 5 µg/mL, respectively, resulted in viable and proliferating cells with 
distinct forward and side scatter flow cytometry characteristics and were therefore 
chosen as optimal concentrations in our experimental model (Figure 3).  
 
 
 
 
 
Figure 3. Optimization of PHA and SEB concentrations measured using the CFSE proliferation 
method following three days of culture.   
Surface and intracellular cytokine staining of CD4+ T cells  
ollowing antigen stimulation, lymphocytes rapidly secrete cytokines. This 
secretion could be measured in the supernatant. However, the amount of 
cytokines in the supernatant does not reflect the number or phenotype of the 
cytokine-producing cells. Surface and intracellular cytokine staining are probably 
two of the most specific methods allowing cytokine production by individual cells to 
be analysed. Both methods are based on flow cytometric detection, which allows the 
use of several fluorescent markers simultaneously, making it possible to couple 
cytokine production to one specific cell type, in our study, the CD4+ T cell. 
 Surface cytokine staining uses a bispecific antibody consisting of a conjugated 
pair of monoclonal antibodies, one directed against the cytokine and the other 
against CD45. CD45 is a leukocyte antigen present on the surface of all nucleated 
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cells. For the intracellular staining procedure, the cell membrane must be 
permeabilized to allow anti-cytokine antibodies to enter the cytoplasm. Following 
cytokine labelling, a fluorochrome-conjugated anti-CD4 antibody is used for 
selecting Th cells. In contrast to surface cytokine staining, intracellular staining 
reveals the number of cells that synthesize the cytokine and not the number that 
actively secrete the cytokine. In addition, intracellular staining results in non-viable 
cells, since the assay procedure includes blocking the cytokine secretion by brefaldin 
A, permeabilization of the plasma membrane, and cell fixation. 
 Surface cytokine staining is considered a more sensitive method than 
intracellular cytokine staining. In an experiment performed by Desombere et al., in 
which a defined number of IFN-γ-producing cells were added, the correlation 
coefficient for detected cells was 0.999. It was also shown that as few as 20 IFN-γ-
producing cells could be reliably detected [Desombere 2004; Desombere 2005]. 
Higher sensitivity was also apparent in a control experiment performed in our 
laboratory in which surface cytokine staining was used to estimate cytokine 
production following three days of stimulation. The percentage of responding IFN-
γ-producing CD4+ T cells detected was approximately 40% for surface cytokine 
staining, but only 4% for the intracellular cytokine staining (data not shown). 
However, Oelke et al. reported good correlation, with similar degrees of detection, 
between surface and intracellular cytokine staining (r = 0.83) [Oelke 2000].
 We have used both PBMC and whole blood in our analyses. Some reports have 
compared the use of whole blood and PBMC. Using intracellular cytokine staining, 
Suni et al. reported similar frequencies of activated T cells in PBMC and blood [Suni 
1998]. In contrast, Hoffmeister et al. reported consistently higher response in PBMC 
than in whole blood, and concluded that the use of whole blood, could, if anything, 
underestimate the frequency of antigen-specific T cells [Hoffmeister 2003]. 
Proliferation  
he 3H-thymidine incorporation proliferation assay has long been used to 
measure bulk cell division. We established a flow cytometry-based method in 
which cells are pre-labelled with the fluorescent dye 5,6-carboxylfluorescein 
diacetate succinimidyl ester (CFSE). CFSE consists of a fluorescent molecule 
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containing two acetate moieties and a succinimidyl ester functional group. In this 
form, CFSE is membrane permeant and non-fluorescent. After diffusion, 
endogenous esterases cleave the acetate group, making the non-fluorescent molecule 
fluorescent and non-permeant. Proliferation is detected as a decrease in 
fluorescence, as the amount of CFSE is diluted by each cell cycle. The CFSE method 
makes it possible to measure the number of cell divisions and to detect specific cell 
types. 
 CFSE concentration and days of culture were optimized. A concentration of 9 µM 
of CFSE and a culture time of three days were found to be optimal for our 
experimental model. The proportion of responding cells, i.e., the percentage of 
proliferating lymphocytes, was calculated by dividing the number of proliferating 
cells as detected in M2 by the total number of lymphocytes, M1 + M2 (Figure 4).  
 
 
 
 
 
 
 
Figure 4. A typical histogram showing gate settings of CFSE-labelled lymphocytes.  
Cytokines in supernatants from cultured PBMC 
o quantify cytokines in supernatant from cultured PBMC, the flow cytometry-
based cytokine bead array (CBA) method was used. CBA allows the 
simultaneous measurement of several different cytokines in as little as 25 µL of 
sample, compared with approximately 250 µL per well and cytokine in an ELISA. 
The method uses a mixture of beads coated with specific antibodies against each 
cytokine. The beads are uniform in size but contain different intensities of the 
fluorescence dye phycoerythrine. This is a solution-based method, which makes it 
more efficient in capturing antigens than a static surface like an ELISA plate [Tarnok 
2003]. 
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Allelic discrimination using TaqMan real-time PCR 
dentifying single nucleotide polymorphisms (SNPs) has become a useful tool for 
investigating the genetic influence on various diseases. We determined the 
frequency of two known polymorphisms, one at position +874 in the first intron of 
the IFN-γ gene and one at position -168 of the MHC2TA gene, by using allelic 
discrimination with TaqMan real-time PCR. This method is highly accurate and 
reproducible for analyses of polymorphisms. Detection of the two alleles is achieved 
by differentiating between allele-specific probes. Bound probes are cleaved by 5’ 
nuclease activity, which in turn generate a permanent assay signal. All probes used 
were minor groove binding probes (MGB), which bind to and stabilize the DNA 
helix. All MGB probes include a non-fluorescent quencher to decrease background 
fluorescence, leading to increased sensitivity. We used control DNA of known 
genotypes, a kind gift from H. Nissbrandt and I. Kockum, previously verified by 
pyrosequencing and allelic discriminating TaqMan PCR, for each analysed SNP of a 
total of 12 individuals. Of a total of n = 470 patients and n = 425 controls, genotype 
was determined in all but one patient and one healthy control, IFN-γ and MHC2TA, 
respectively. 
 For IFN-γ (rs2430561), primer and probes earlier described by Rad et al. were 
used [Rad 2004] as follows: forward primer 5´ATT CAG ACA TTC ACA TTC ACA 
ATT GAT TTT ATT CTT AC 3´and reverse primer 5´ACT GTG CCT TCC TGT AGG 
GTA TTA TT 3´; probe 1, 5´MGB-AAT CAA ATC TCA CAC ACA C 3´-FAM, and 
probe 2, 5´MGB-ATC AAA TCA CAC ACA CAC 3´-VIC. The primer-to-probe 
concentration, reaction volume, and minimum concentration of DNA used in the 
PCR and allelic discrimination were optimized based on the cycle threshold values. 
Consequently, the reactions were carried out in a 96-well plate in a total volume of 
15 µL containing approximately 60 ng of genomic DNA, 300 nM of each primer, and 
50 nM of each probe. 
 For MHC2TA (rs3087456), pre-designed primers and probes were used (Applied 
Biosystems, New Jersey, US). A disadvantage of using pre-designed primers and 
probes is that the nucleotide sequences are unavailable to the customer, while the 
advantage is that they usually do not need further optimization and the total 
reaction volume is low. The PCR and end-point analysis for MHC2TA were carried 
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out in a 96-well plate in a total volume of 10 µL, with approximately 60 ng of 
genomic DNA. 
 Allelic discrimination analyses were performed on an ABI Prism 7900HT 
Sequence Detecting System using the SDS 2.1 software program. 
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RESULTS AND DISCUSSION 
nflammatory cytokines are today considered part of the heart failure syndrome. 
It is not clear, however, whether cytokines act as an initiating factor in the 
development of the disease or are a consequence of it. Immunological factors, such 
as the high frequency of autoantibodies, presence of viral genomes in myocardial 
biopsies, and elevated plasma cytokines, have been identified in patients with DCM. 
Considerably less is known about T cell function in DCM, which therefore has been 
the main focus in this thesis. The role of our findings will be interpreted in relation 
to infection and autoimmunity. 
 
INCREASED PERIPHERAL IMMUNE ACTIVITY  
onsistent with previous studies, we found increased levels of IFN-γ, TNF-α, 
IL-6, IL-10, and CRP in patients with DCM (papers I and II) [Levine 1990; 
Mann 2002; Ishikawa 2006]. This general increase of cytokine levels in plasma 
indicates chronic immune activation. Two hypotheses regarding enhanced immune 
activation can be found in the literature, namely, pathogen-driven and cardiac 
injury-driven activation, i.e., tissue antigens are exposed and capable of triggering 
an immune response [Torre-Amione 2005]. Pathogen-driven activation leading to 
myocarditis and its sequela, DCM, has been frequently reported following viral 
infections; initiation of DCM due to bacterial infections is less common [Kuhl 2005; 
Kuhl 2005; Davydova 2000]. A cardiac injury-driven activation can be seen following 
myocardial infarction where self-antigens are exposed and capable of triggering an 
immune response against the heart. In a rat model, self-reactive cytotoxic T cells 
have been detected and shown to exhibit direct cytotoxic effects on non-affected 
cardiomyocytes in vitro following myocardial infarction resulting in tissue damage 
[Varda-Bloom 2000]. In addition, increased bowel wall permeability accompanied 
by the translocation of endotoxins from the gut to the peripheral circulation has also 
been reported as one possible cause of the increased immune activity [Sandek 2007; 
Niebauer 1999]. 
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The impact of cytokines on cardiac function 
e found poor NYHA function class to be associated with increased plasma 
levels of IL-6 and CRP, but not with increased levels of TNF-α or IL-10 
(paper I). We also found elevated IL-6, IL-10, and CRP levels to correlate with 
diastolic filling pressure (paper I). The association between NYHA function class 
and both IL-6 and TNF-α has been shown earlier [Torre-Amione 1996]. We do not 
have a clear explanation for the lack of association with NYHA and TNF-α in our 
study. It could depend on the composition of patients, as elevated TNF-α levels 
mostly has been found in severe heart failure only. 
 The exact function and clinical significance of these cytokines in DCM and heart 
failure are poorly understood. The cytokine network is extremely complex, and one 
cytokine is enough to induce several others, affecting the outcome of an immune 
response. TNF-α is one of the most frequently studied cytokines in DCM, and quite 
apart from its inflammatory action, it is known to have direct negative inotropic 
effect on the myocardium by reducing the level of intracellular calcium during the 
systolic contraction phase [Yokoyama 1993]. Furthermore, TNF-α results in 
interstitial fibrosis, apoptosis, and ventricular remodelling, inducing left ventricular 
dilatation of the myocardium [Bradham 2002]. TNF-α induces the expression of IL-6, 
which is also known to have negative inotropic effects on cardiomyocytes [Finkel 
1992]. IL-6, in turn, is further implicated in left ventricular remodelling and the 
development of ventricular hypertrophy through enhanced stimulation of the 
glycoprotein (gp) 130 receptor subunit expressed on cardiac myocytes [Kunisada 
1996]. In fact, Aukrust et al. demonstrated increased expression of the soluble gp130 
protein in heart failure [Aukrust 1999]. IL-6 is also known to rapidly induce CRP, 
which binds to a variety of microorganisms and induces a proinflammatory immune 
response. Although the matter has not been extensively studied, there are reports of 
elevated levels of CRP in heart failure and DCM [Ishikawa 2006]. CRP is known to 
have direct proinflammatory effects on human endothelial cells by increasing the 
expression of adhesion molecules such as ICAM-1, VCAM-1, and E-selectin [Pasceri 
2000]. In fact, ICAM-1, VCAM-1, and soluble P-selectin have been associated with 
adverse clinical outcome in heart failure [Yin 2003]. In addition, endothelial 
dysfunction has been reported to influence the progression of heart failure, which 
indicates an important role for CRP in the pathophysiology [Chong 2004; Katz 2005]. 
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The question of whether the heart itself is a source of cytokine production has been 
raised but the results are contradictory [Mann 1999; Munger 1996; Tsutamoto 2004]. 
We measured cytokine concentrations in the coronary sinus and systemic arterial 
blood without finding any difference between these two locations (Table 4).  
Table 4. Cytokine gradient across the myocardium in patients with DCM.  
 Transmyocardial gradient 
 Artery Coronary sinus p-value 
TNF-α 2.41 ± 0.92 2.36 ± 0.91 0.74 
IL-6 2.16 ± 0.41 2.15 ± 0.44 0.77 
IL-10 0.88 ± 0.12 0.89 ± 0.18 0.73 
IL-6, interleukin-6 (n = 19); IL-10, interleukin-10 (n = 9); TNF-α, tumor necrosis factor α (n = 16). 
Values are expressed as mean ± SEM pg/mL. 
Increased lymphocyte activity 
n addition to increased levels of cytokines in plasma, we also found elevated 
surface expression of both CD3 and the α-subunit (CD25) of the IL-2 receptor in 
patients with DCM (paper II). This indicates increased numbers of circulating T cells 
in the periphery together with increased immune activation. CD25 is considered an 
early activation marker expressed on T cells after the triggering of the TCR. The 
expression occurs within 2–24 h of stimulation and persists for only a few days if the 
stimulation is withdrawn [Poulton 1988]. Our findings are supported by Yndestad et 
al., who reported increased CD25 expression on both CD4+ and CD8+ T cells in 
chronic heart failure [Yndestad 2003]. 
Reduced production of IL-10  
e found significantly and independently lower levels of IL-10 in patients 
with DCM than in patients with IHD even after incorporating of etiology, 
age, gender, and clinical variables in a multivariate analysis. To the best of our 
knowledge, this has not previously been demonstrated (paper I). 
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IL-10 is a major regulatory cytokine, down-regulating an enhanced immune 
response in order to limit collateral tissue damage and control peripheral 
autoreactivity [Murray 2005; O'Garra 2007; Gazzinelli 1996]. Knowing the function 
of IL-10, as well as the fact that autoantibodies against various heart antigens are 
frequently present in patients with DCM, in sharp contrast to IHD, the difference 
between DCM and IHD shown in this study is intriguing [Magnusson 1990; 
Magnusson 1994; Caforio 2008]. In addition, prevalence of viral genomes and viral 
persistence in the myocardial biopsies are detected in up to 50% of DCM [Why 1994; 
Kuhl 2005; Kuhl 2005; Magnusson 1990; Magnusson 1994]. Few reports have focused 
on comparing cytokine production in DCM and IHD. However, Fukunaga et al. 
studied in vitro activation of IFN-γ-producing CD4+ T cells and found significantly 
lower response in patients with DCM than in IHD [Fukunaga 2007]. 
 We also found significantly lower production of IL-10 in the supernatant of 
cultured PBMC from patients with DCM than from healthy controls (paper II). 
 We speculate that these impaired IL-10 responses in patients with DCM could be 
insufficient in magnitude to fully control an infection, therefore increasing the 
likelihood of a disease of autoimmune character. The protective role of IL-10 is 
shown by its ability to reduce proinflammatory cytokines, such as, IFN-γ, TNF-α, 
and IL-2, in experimental autoimmune myocarditis [Gazzinelli 1996; Li 2005]. 
Notably, intravenous immunoglobulin treatment of patients with DCM has been 
shown to result in a marked increase of IL-10, which in turn correlated significantly 
with improved left ventricular ejection fraction [Gullestad 2001]. 
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REDUCED T CELL ACTIVITY IN VITRO 
CM is a heterogeneous disease with several different etiologies and disease 
mechanisms. Measuring plasma cytokines only indicates whether there is 
ongoing immune activity without revealing anything about the cause of the altered 
production. It is therefore of great interest to use more specific methods to study T 
cell function. 
Reduced response of IFN-γ-producing CD4+ T cells  
n DCM, we observed a profound reduction in the number of responding IFN-γ-
producing CD4+ T cells following stimulation with SEB and PHA, while there 
was no difference in the number of responding IL-4-producing CD4+ T cells (paper 
II). Decreased numbers of responding IFN-γ- but not of IL-4-producing CD4+ T cells 
have also been reported in patients with autoimmune type 1 diabetes [Kukreja 
2002]. 
 IFN-γ production measured in supernatant from stimulated PBMC has been 
shown to correlate well with the number of responding IFN-γ-producing CD4+ T 
cells [Desombere 2005]. We found further support for a defective IFN-γ response in 
DCM, seen by a significantly lower IFN-γ production from overnight non-stimulated 
PBMC, while no difference was found for IL-4. The reduced IFN-γ production in the 
supernatant was in the same range as the reduced mRNA expression of IFN-γ 
detected in the resting blood of newly diagnosed diabetic patients [Halminen 2001]. 
 These findings were somewhat unexpected with regard to our hypothesis, 
according to which we expected elevated IL-4 production based on the presence of 
autoantibodies in these patients. Since the IL-4 production was found to be normal, 
the impaired IFN-γ was most likely not a result of any suppressive effects of IL-4. 
The balance of the Th1 (IFN-γ) and Th2 (IL-4) response was first proposed as a major 
regulatory mechanism of autoimmunity. Organ-specific autoimmune diseases have 
been suggested to have an increased Th1 response [Charlton 1995]. However, this 
simple classification has today been reassessed and may no longer be strictly 
applicable. 
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The importance of CD4+ T cells in activating a sufficiently strong CD8+ cytotoxic T 
cell response during infection is well known [Battegay 1994; Matloubian 1994]. This 
was shown in both CD4+ and CD8+ T cell-deficient mice immunized with the cardiac 
myosin peptide to induce organ-specific autoimmunity. Immunization of CD4+-
deficient mice resulted in the development of autoimmune myocarditis with 
autoantibody production, whereas immunization of CD8+-deficient mice resulted in 
a more aggravated disease [Penninger 1993]. 
 Taken together, our results indicate a defect in the IFN-γ response. This is 
reinforced by the lack of differences in the IL-4 response, in both the number of 
responding CD4+ T cells and IL-4 levels in the supernatant. 
Reduced lymphocyte proliferation 
ollowing three days of stimulation with SEB, there was a significant proportion 
of lymphocytes undergoing proliferation compared with non-stimulated cells. 
However, this proliferative response was significantly lower in patients with DCM 
than in controls (paper II). An impaired proliferative response to Mycobacterium bovis 
has been described in patients with DCM and has been found to correlate with 
disease progression [Bromelow 1997]. We did not observe any difference when 
stimulating with PHA (data not shown). This could be because PHA is dependent 
on accessory cells for T cell stimulation and would be expected to need a longer time 
to exert the same effect as seen with SEB. T cells need to be stimulated and to have 
initiated cytokine production before they can proliferate. 
 Even though we did not specifically study CD4+ T cell proliferation, we surmise 
that the decreased proliferation most likely reflects reduced Th cell activity. In the 
peripheral blood of our patients, approximately 60% of the lymphocytes were CD4+, 
the remaining population consisting of 30% cytotoxic T cells and 10% B cells (data 
not shown). Despite impaired proliferation in DCM, we observed no significant 
differences between DCM and controls in the IL-2 levels measured in supernatants 
following either overnight or three days of SEB stimulation (data not shown). Since 
IL-2 is a major proliferative cytokine, one would have expected the decreased 
proliferation to be visible in the IL-2 levels. Therefore, it seems reasonable to believe 
that there is some sort of T cell defect present in DCM, possibly a defect in the TCR 
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signalling. SEB stimulation has been shown to result in phosphorylation of the TCR 
ζ-subunits. Such a connection has been described in haemodialysis patients, who 
displayed lower proliferation following SEB stimulation, caused by impaired 
phosphorylation of the ζ-chain [Niedergang 1998; Eleftheriadis 2004]. 
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GENETICS OF DCM 
pproximately 30–50% of cases of DCM are believed to have a genetic 
background, autosomal dominant inheritance being the usual form. Although 
genetic factors seem to be important, only a minority of known mutations have been 
associated with familial DCM. The first familial DCM was reported as early as 1949, 
whereas the first DCM-associated mutation, detected in the dystrophin gene, was 
characterized in 1993 [Towbin 1993]. Linkage analysis is difficult to perform due to 
the limited size of families and difficulties in the diagnosis of DCM. Today, over 20 
mutations have been characterized in various cardiac-specific proteins leading to 
DCM. Considerable less is known about mutations in immunological proteins and 
their possible association to DCM. Two of the most frequently reported 
polymorphisms associated with various autoimmune diseases are found within the 
human leukocyte antigen (HLA) and the CTLA-4 surface molecule genes. The HLA 
is the antigen-presenting molecule in humans corresponding to the MHC molecule 
in animals [Bilbao 2003; Li 2008]. The IFN-γ polymorphism at position +874 has been 
of interest in inflammatory and autoimmune disorders such as hepatitis B, 
Wegener’s granulomatosis, and Hashimoto’s disease [Spriewald 2005; Ito 2006; Ben-
Ari 2003]. 
 We investigated the frequency of the polymorphism at position +874 in the IFN-γ 
gene and at position –168 in the MHC2TA gene in patients with heart failure. Both 
polymorphisms have been associated with differential transcription levels [Pravica 
1999; Pravica 2000; Swanberg 2005]. To the best of our knowledge, we are the first to 
report a significant association between the high producing IFN-γ genotype and 
susceptibility to DCM. In contrast to IFN-γ, there was no difference in the MHC2TA 
polymorphism between patients and controls. There were no associations between 
either of these polymorphisms and 10-year mortality (paper III). 
 Interestingly, Rheka et al. reported an association between the high-producing 
IFN-γ genotype TT and Hashimoto's thyroiditis, whereas the low-producing IFN-γ 
genotype was associated with Graves’ disease; the former disease is caused by 
autoreactive T cells and the latter by antibody-mediated immune reactions [Rekha 
2006]. The direct anti-inflammatory effect of intravenous immunoglobulin 
treatment, which has been used successfully in DCM and shown to lead to 
improved cardiac function, has been linked to blockade of IFN-γ gene expression  
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and signalling [Park-Min 2007]. The role of IFN-γ polymorphism in heart failure has 
been sparsely investigated. It has been studied in regard to the progression to end-
stage heart failure in children with cardiomyopathy or congenital heart disease, 
without any association being found [Webber 2002]. As shown in Figure 5, we found 
no association between the IFN-γ genotype and the number of IFN-γ responding 
CD4+ T cells in either patients or controls (Figure 5). 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 5. The percentage of IFN-γ-producing CD4+ T cells in relation to IFN-γ transcription 
phenotype (low, intermediate, and high) in (A) healthy controls and (B) patients with DCM.  
IFN-γ is a strong inducer of MHC expression, which in turn is controlled by 
MHC2TA. Aberrant HLA expression, especially HLA-DR4, has been reported in 
DCM. In addition, increased numbers of T cells expressing HLA-DR are found in the 
periphery of patients with DCM [Carlquist 1991; Ueno 2007]. The allele and 
genotype frequencies in our study were in the same range as reported by Swanberg 
et al.; they also reported an association between the G-allele and rheumatoid 
arthritis, multiple sclerosis, and myocardial infarction [Swanberg 2005]. Several 
studies have failed to confirm these results, however. Neither did we found any 
significant associations between the MHC2TA gene polymorphism and DCM or 
mortality. This is in contrast to the observed increased mortality in patients with 
type 1 diabetes and previous myocardial infarction having the low expressing 
variants of MHC2TA [Lindholm 2006]. 
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IS THERE AN ACTUAL T CELL DEFECT IN DCM? 
e have demonstrated impaired in vitro production of IFN-γ and IL-10 in 
CD4+ T cells and PBMC, respectively. This is in contrast to the increased 
peripheral levels of these cytokines and to the higher genetic ability to produce IFN-
γ. It is important to discuss the experimental conditions used and to rule out factors 
that could have influenced the in vitro results, such as SEB specificity, anergy, and 
apoptosis.  
 SEB is a potent superantigen produced by the Staphylococcus aureus bacterium. 
Superantigens stimulate a large fraction of T cells by cross-linking the MHC class I 
or II on antigen-presenting cells and the corresponding TCR on CD4+ and CD8+ 
cells. SEB is therefore considered a strong physiological stimulator of T cells. This 
bridge bypasses the antigen processing and presenting step needed during normal 
antigen activation. SEB is known to bind specifically to certain T cell subsets 
expressing the TCR Vβ-3, -12, -14, or -17 chains in humans. This specificity could 
skew the results in an in vitro model such as ours [Choi 1989]. However, in our 
study, the reduced response of IFN-γ-producing CD4+ T cells was also apparent in 
the case of PHA stimulation. PHA is a non-specific mitogen-binding extracellular 
carbohydrate structure and is dependent on accessory cells for activation of T cells 
[Ijichi 1996]. 
 What about anergy and apoptosis? Indeed, it is possible that PBMC isolated from 
patients with DCM displaying increased peripheral immune activation could 
already be in an anergic state of unresponsiveness or enter apoptosis when 
stimulated in vitro, i.e., activation-induced cell death [Song 2004; Kishimoto 1999; 
Redmond 2005]. An important consideration in this regard is the significantly 
reduced levels of IFN-γ found in the supernatant following overnight incubation 
without stimulation, despite the increased plasma levels of IFN-γ. If the reduced 
IFN-γ levels were due to increased anergy and apoptosis in vivo, this would then 
also be evident in peripheral cytokine levels. Although, to the best of our 
knowledge, lymphocyte apoptosis has not been reported for DCM, increased 
apoptosis in cardiomyocytes has been reported [Kuethe 2007]. 
 In experiments measuring both the CD4+ T cell response and the PBMC 
production of cytokines, the anti-CD28 co-stimulatory molecule was added. Co-
stimulation via CD28 is known to support T cell proliferation as well as survival.  
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CD28 counteracts the activation-induced cell death pathway by up-regulating pro-
apoptotic molecules such as BCL-xL [Boise 1995; Kerstan 2004]. 
 DCM is a progressive disease and may display different pathophysiology 
depending on disease duration. However, we did not find any correlation between 
disease duration and the number of responding IFN-γ-producing CD4+ T cells 
(Figure 6). This lack of correlation means that the reduced number of IFN-γ-
producing CD4+ T cells in DCM reflects a mechanistic defect rather than a variable 
dependent on degree of heart failure. 
   
 
 
 
 
  
 
 
 
 
 
 
 
Figure 6. The percentage of IFN-γ-producing CD4+ T cells in relation to heart failure duration. 
The consistently normal IL-4 responses together with the lack of correlation between 
disease duration and the IFN-γ response further support the conclusion that the 
altered IFN-γ is a true defect in the immune response of DCM. Having ruled out 
possible influencing factors, the next question is, what impact would aberrant IFN-γ 
and IL-10 production have on infection and autoimmunity? 
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DUAL ROLE OF IL-10 AND IFN-γ IN THE REGULATION OF                
INFECTION AND AUTOIMMUNITY 
 
Some patients seem to die not of their infection 
but of the body’s response to it. 
       William Osler, 1849–1919 
 
hortly after autoimmune diseases were first recognized, they were associated 
with viral infections. Today, however, no autoimmune diseases have been 
consistently linked to a specific microorganism. Instead, several viruses have been 
associated with one disease. It is possible that viruses play a contributory rather 
than a causative role. Following infection with the cytomegalovirus in mice, 
Fairweather et al. demonstrated the development of myocarditis with a late, chronic 
phase of the disease. This phase was similar to the infection observed following 
immunization with the cardiac myosin antigen [Fairweather 2001]. In fact, this late, 
chronic phase of cytomegalovirus infection meets the criteria of an autoimmune 
disease by (1) being reproduced by immunization with a relevant organ-specific 
antigen, (2) causing production of autoantibodies, and (3) the ability to adoptively 
transfer with T cells from affected to non-infected mice [Rose 1993; Witebsky 1957]. 
 It is therefore of interest to understand the adjuvant effects, such as cytokine 
production and the regulation of immune response during infection, instead of 
focusing on the pathogen itself. 
IL-10 
L-10 is beneficial to both the host and the virus: to the host by limiting the 
immunopathology defined as damage caused to the host by the immune 
response as a result of infection, and to the virus by allowing transformation from 
an acute to a chronic phase of infection. Beneficial host effects have been shown in 
mice infected with encephalomyocarditis virus where treatment with recombinant 
human IL-10 resulted in significantly improved survival and attenuated myocardial 
lesions [Nishio 1999]. Strategies for augmenting pathogen clearance in order to 
prevent chronic infections have resulted in exacerbated tissue damage. IL-10- 
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deficient mice inoculated with Toxoplasma gondii and Trypanosoma cruzi were found 
to succumb to lethal infections due to overproduction of IFN-γ. The mortality seen 
following T. cruzi infection could be reversed by administration of recombinant IL-
10 or neutralizing antibodies specific to IL-12 [Gazzinelli 1996; Hunter 1997]. Similar 
aggravating effects of an IL-10 deficiency have been shown in hepatitis, herpes 
simplex virus-1, and HIV, to mention a few [Couper 2008]. This indicates that 
maximal pathogen clearance does not necessarily lead to reduced disease 
prevalence. Instead, it indicates the importance of a properly balanced immune 
response. A strong regulatory response by IL-10 at the beginning of an infection 
may result in inadequate pathogen clearance due to its suppressive effects on 
proinflammatory cytokines, while an insufficient response may result in severe 
immunopathology due to the over-activation of proinflammatory cytokines. 
 IL-10 is known to control the proinflammatory arm of the immune system, such 
as TNF-α release. Exogenous administration of IL-10 has been reported to protect 
against tissue injury induced by TNF-α-mediated oxidative stress [Mulligan 1993]. 
In addition, IL-10 has also been shown to shift the protease–antiprotease balance 
favouring matrix preservation and tissue healing [Lacraz 1995]. Uncontrolled 
proinflammatory cytokine production can induce undesirable outcomes, such as 
autoimmune reactions due to activation of macrophages and cytotoxic T cells. These 
cells cause collateral damage to normal tissue by the release and leakage of 
proteases and reactive oxygen, which in turn causes exposure of self-antigens and 
activates an immune response (Figure 7). This could be one plausible hypothesis as 
to what is observed in DCM, a chronic immune activity with autoimmune 
characteristics possibly caused by insufficient levels of IL-10 to control the immune 
activity. 
 The complexity of the IL-10 response and its regulatory mechanisms has made it 
difficult to sort out the role of specific IL-10-producing cells during infection. 
However, in virulent infections, naturally occurring Treg cells are insufficient to 
control the magnitude of the immune response. Instead, the important inducible 
Treg cells producing IL-10, generated in the periphery, take over and act in an 
antigen-dependent manner [Shevach 2006]. In our study, we were unable to identify 
the type of cell responsible for the impaired production of IL-10. However,  
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irrespective of the source, IL-10 seems to have similar effects on various infections 
[Couper 2008]. 
  
 
 
 
 
 
 
 
 
 
 
Figure 7. The vicious circle of an over-activated immune response. ↑, increased; MQ, macrophages. 
IFN-γ 
ver the past few years, the Th1 cytokine IFN-γ has been shown to have 
regulatory functions and to influence autoimmune reactions. Depending on 
the disease, it has been shown to function as both a disease-promoting and -
inhibiting component. In animal models in which either IFN-γ or the IFN-γ receptor 
were genetically deleted, most autoimmune diseases, for example, experimental 
autoimmune encephalomyelitis, collagen-induced arthritis, and uveitis, resulted in 
increased disease progression and severity [Rosloniec 2002]. In experimental 
autoimmune myocarditis, IFN-γ deficiency resulted in exacerbated myocarditis and 
the development of fatal autoimmune disease [Afanasyeva 2001; Eriksson 2001]. 
There are conflicting findings as to the precise role of IFN-γ in autoimmunity. 
However, Wang et al. reported IFN-γ to be a strong inducer of Foxp3 expression in 
experimental autoimmune encephalomyelitis and important for the conversion of  
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CD4+CD25– T cells into CD4+ Treg cells, in both mice and humans [Wang 2006]. This 
is in line with the association found by Afanasyeva et al. between the impaired up-
regulation of CD25 expression on CD4+ T cells in IFN-γ-deficient mice and the 
progression of myocarditis to DCM. [Afanasyeva 2005]. Yet another control 
mechanism exerted by IFN-γ-producing Th1 cells is the co-production of IL-10 in a 
self-controlling manner following infection with Toxoplasma gondii [Jankovic 2007]. 
 Taken together, not only IL-10, but also IFN-γ is important for the induction and 
regulation of Treg cells and the development of autoimmune diseases (Figure 8). 
This strengthens the importance of our findings of impaired IFN-γ as well as IL-10 
production in DCM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Effects of altered IFN-γ production on the immune response. 
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THE IMPACT OF HEART FAILURE TREATMENT ON                                                  
THE IMMUNE SYSTEM 
t is well documented that the sympathetic nervous system plays a major role in 
cardiovascular disease. Patients with heart failure have profoundly elevated 
levels of catecholamines; these in turn have been shown to have deleterious effects 
in experimental studies of mammalian cardiomyocytes, in which higher levels lead 
to decreased myocyte viability [Mann 1992]. In addition, norepinephrine, in 
particular, has been shown to be independently related to the risk of heart failure 
progression and mortality [Cohn 1984]. In turn, norepinephrine is known to alter the 
activity of the immune system through the signalling of β-adrenergic receptors, 
which are known to be expressed on T and B cells [Sanders 2002]. Norepinephrine is 
believed to increase sympathetic drive which leads to increased immune activity, 
most often seen as increased cytokine levels. It is therefore of importance to discuss 
the impact of heart failure treatment on immunological studies. 
 A major breakthrough in the treatment of heart failure came in mid 1970 when 
Waagstein et al. reported improved cardiac function following β-blocker treatment 
of patients with heart failure. Today β-blockers and angiotensin-converting enzyme 
(ACE) inhibitors are mandatory in the treatment of heart failure [Waagstein 1975]. 
This treatment reduces sympathetic activity by lowering plasma norepinephrine, 
and thereby also immune activity. Most significant is the influence of ACE inhibitors 
by lowering plasma IL-6 and of β-blockers by lowering plasma TNF-α. However, 
even following heart failure therapy, a high degree of immune activation persists 
[Gullestad 1999; Ohtsuka 2001]. 
 Of patients with DCM in whom we measured plasma cytokines, 92% and 99% 
received β-blockers and ACE inhibitors, respectively, in paper I, whereas 88% and 
100% of patients were treated in paper II. All patients received β1-selective β-
blockers. This would not have any direct blocking effect on immune cells, since they 
lack the β1-AR [Kohm 2001; Sanders 2002]. Levels of IL-6 and TNF-α in plasma are 
elevated in patients with DCM and heart failure despite treatment with β-blockers 
and ACE inhibitors (papers I and II). It could be speculated that the results observed 
in paper II, in which decreased responses of both IFN-γ and IL-10 were observed, 
were partly due to treatment effects. This is not particularly likely, since we found 
I 
 
RESULTS AND DISCUSSION 
 
 
 
 - 54 - 
no difference between DCM and controls in either IL-6 or TNF-α production 
measured in the supernatant from cultured PBMC (Table 5). 
Table 5. TNF-α and IL-6 measured in the supernatant from PBMC cultured overnight. Values are 
expressed as mean ± SEM. 
 TNF-α  IL-6 
 Controls DCM p-value  Controls DCM p-value 
Basal 2460 ± 330 2270 ± 440 0.45  14 400 ± 1500 18 600 ± 3000 0.66 
SEB 2430 ± 220 2950 ± 330 0.35  12 600 ± 1100 17 800 ± 2400 0.09 
PHA 2340 ± 240 2880 ± 360 0.32  14 000 ± 1400 19 100 ± 3600 0.56 
 
 
In a study designed to evaluate heart failure therapy, Gage et al. reported that the 
TNF-α production and IFN-γ/IL-10 ratio of stimulated PBMC was significantly 
lower in treated than untreated patients [Gage 2004]. 
 Finally, the immune system and sympathetic nervous system are two complex 
networks in the human body. How and the extent to which these two systems 
regulate one another is still controversial, so it is difficult to interpret the possible 
effects of conventional heart failure therapy on T cell function. 
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CONCLUSION 
his thesis aimed to study T cell function in DCM. Our results are consistent 
with the general belief that DCM is a disease with immunological 
pathophysiology. The major immunological alterations reported in DCM, i.e., 
presence of autoantibodies and elevated cytokines in plasma, indicate chronic 
peripheral immune activity in these patients. We suggest that this chronic immune 
activity is a consequence of a reduced capacity to regulate the immune response, 
seen by decreased ability to produce INF-γ and IL-10. Dysfunctional immune 
regulation dramatically increases the risk of both chronic infections and 
autoimmune reactions. 
 However, we have only studied a minor part of the complex area of 
immunology, and there is much more to explore in order to define what impact the 
immune system has on DCM. Here, we offer one piece of the major puzzle that is 
DCM and encourage others to continue this line of research, by defining T cell 
function in DCM. 
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